Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -6.95 is 92% above its 5-year average of -91.58, near the high end of its 5-year range (-179.25–-6.10).
68.66% above its 12-month average of -22.18.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -2.25.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 16 comparable quarters.
EARNINGS PER SHARE (EPS)
-6.95
EARNINGS PER SHARE (EPS) AVG TTM
-22.18
EARNINGS PER SHARE (EPS) AVG 3Y
-69.66
EARNINGS PER SHARE (EPS) AVG 5Y
-91.58
EARNINGS PER SHARE (EPS) AVG 10Y
N/A
EARNINGS PER SHARE (EPS) AVG 15Y
N/A
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
+68.66%
CURRENT VS 3Y AVG
+90.02%
CURRENT VS 5Y AVG
+92.41%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
CalciMedica, Inc.
Market Cap
$4.63M
Earnings Per Share (EPS)
-6.95
TTM Avg
-22.18
3Y Avg
-69.66
5Y Avg
-91.58
Market Cap
$4.61M
Earnings Per Share (EPS)
-4.39
TTM Avg
-44.24
3Y Avg
-644.57
5Y Avg
-610.60
Market Cap
$4.92M
Earnings Per Share (EPS)
-3.64
TTM Avg
-254.03
3Y Avg
-3442.01
5Y Avg
-5629.67
Market Cap
$4.71M
Earnings Per Share (EPS)
-2.41
TTM Avg
0.21
3Y Avg
-0.40
5Y Avg
-0.72
Market Cap
$4.83M
Earnings Per Share (EPS)
-1.19
TTM Avg
-2.08
3Y Avg
-2.84
5Y Avg
-5.63
Market Cap
$4.34M
Earnings Per Share (EPS)
-9.39
TTM Avg
-11.95
3Y Avg
-11.32
5Y Avg
-8.88
Market Cap
$4.95M
Earnings Per Share (EPS)
-5.32
TTM Avg
-8.47
3Y Avg
-12.67
5Y Avg
-14.30
Market Cap
$4.96M
Earnings Per Share (EPS)
-4.53
TTM Avg
-13.96
3Y Avg
-30.40
5Y Avg
-166.98
Market Cap
$5.00M
Earnings Per Share (EPS)
-23.70
TTM Avg
-20.75
3Y Avg
-13.28
5Y Avg
-9.32
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| CalciMedica, Inc. (CALC) | $4.63M | -6.95 | -22.18 | -69.66 | -91.58 |
| Dermata Therapeutics, Inc. (DRMA)vs › | $4.61M | -4.39 | -44.24 | -644.57 | -610.60 |
| Bio Green Med Solution, Inc. (BGMS)vs › | $4.92M | -3.64 | -254.03 | -3442.01 | -5629.67 |
| PharmaCyte Biotech, Inc. (PMCB)vs › | $4.71M | -2.41 | 0.21 | -0.40 | -0.72 |
| Xenetic Biosciences, Inc. (XBIO)vs › | $4.83M | -1.19 | -2.08 | -2.84 | -5.63 |
| CollPlant Biotechnologies Ltd. (CLGN)vs › | $4.34M | -9.39 | -11.95 | -11.32 | -8.88 |
| Lexaria Bioscience Corp. (LEXX)vs › | $4.95M | -5.32 | -8.47 | -12.67 | -14.30 |
| Imunon, Inc. (IMNN)vs › | $4.96M | -4.53 | -13.96 | -30.40 | -166.98 |
| Liminatus Pharma, Inc. Class A Common Stock (LIMN)vs › | $5.00M | -23.70 | -20.75 | -13.28 | -9.32 |
| Basel Medical Group Ltd Ordinary Shares (BMGL)vs › | $5.01M | N/A | -1.61 | -0.43 | -0.43 |
Trailing EPS (TTM)
$-6.95
Forward EPS (Est.)
$-3.02
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2024-12-31 | -6.10 |
| 2023-12-31 | -38.25 |
| 2022-12-31 | -116.00 |
| 2021-12-31 | -118.30 |
| 2019-12-31 | -179.25 |
| 2018-12-31 | -165.50 |
